Development of Liposome containing sodium deoxycholate to enhance oral bioavailability of itraconazole

Asian Journal of Pharmaceutical Sciences

Volumn 12, Issue 2, 2017, Pages 157-164

  Sun, Yinghua ^a,a   Zhang, Meiyu ^a   Liu, Chang ^a   Zhou, Shiwei ^b   Zhang, Wenjuan ^a   Wang, Tianyang ^a   Zhou, Mei ^a   Liu, Xiaohong ^a   Wang, Yongjun ^a   Sun, Jin ^a  

^a SHENYANG PHARMACEUTICAL UNIVERSITY   (China)

^b Suihua No 1 hospital   (China)

Author keywords

Dissolution; Intestinal infusion; Itraconazole; ITZ Lip NaDC; Oral bioavailability

Indexed keywords

DEOXYCHOLATE SODIUM; ITRACONAZOLE; LIPOSOME; PHOSPHATIDYLCHOLINE;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; COLON; CONTROLLED STUDY; DIFFERENTIAL SCANNING CALORIMETRY; DISPERSION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG SOLUBILITY; DRUG SYNTHESIS; DUODENUM; ILEUM; INTESTINE ABSORPTION; JEJUNUM; MALE; MICROCAPSULE; NONHUMAN; PARTICLE SIZE; PHYSICAL CHEMISTRY; RAT;

EID: 85013799039     PISSN: 18180876     EISSN: 2221285X     Source Type: Journal    
DOI: 10.1016/j.ajps.2016.05.006     Document Type: Article

References (36)

1. [1] Nakarani, M., Misra, A.K., Patel, J.K., et al. Itraconazole nanosuspension for oral delivery: formulation, characterization and in vitro comparison with marketed formulation. Daru 18 (2010), 84–90.
2. [2] Akkar, A., Muller, R.H., Intravenous itraconazole emulsions produced by SolEmuls technology. Eur J Pharm Biopharm 56 (2003), 29–36.
3. [3] Thakkar, H.P., Khunt, A., Dhande, R.D., et al. Formulation and evaluation of Itraconazole nanoemulsion for enhanced oral bioavailability. J Microencapsul, 2015, 1–11.
4. [4] Li, Z., Han, X., Zhai, Y., et al. Critical determinant of intestinal permeability and oral bioavailability of pegylated all trans-retinoic acid prodrug-based nanomicelles: chain length of poly (ethylene glycol) corona. Colloids Surf B Biointerfaces 130 (2015), 133–140.
5. [5] Zhang, K., Yu, H., Luo, Q., et al. Increased dissolution and oral absorption of itraconazole/Soluplus extrudate compared with itraconazole nanosuspension. Eur J Pharm Biopharm 85 (2013), 1285–1292.
6. [6] Kumar, S., Shen, J., Burgess, D.J., Nano-amorphous spray dried powder to improve oral bioavailability of itraconazole. J Control Release 192 (2014), 95–102.
7. [7] Lang, B., Liu, S., McGinity, J.W., et al. Effect of hydrophilic additives on the dissolution and pharmacokinetic properties of itraconazole-enteric polymer hot-melt extruded amorphous solid dispersions. Drug Dev Ind Pharm, 2015, 1–17.
8. [8] DiNunzio, J.C., Hughey, J.R., Brough, C., et al. Production of advanced solid dispersions for enhanced bioavailability of itraconazole using KinetiSol Dispersing. Drug Dev Ind Pharm 36 (2010), 1064–1078.
9. [9] Li, D.X., Park, Y.J., Oh, D.H., et al. Development of an itraconazole-loaded gelatin microcapsule with enhanced oral bioavailability: physicochemical characterization and in-vivo evaluation. J Pharm Pharmacol 62 (2010), 448–455.
10. [10] Miller, M.A., DiNunzio, J., Matteucci, M.E., et al. Flocculated amorphous itraconazole nanoparticles for enhanced in vitro supersaturation and in vivo bioavailability. Drug Dev Ind Pharm 38 (2012), 557–570.
11. [11] Mou, D., Chen, H., Wan, J., et al. Potent dried drug nanosuspensions for oral bioavailability enhancement of poorly soluble drugs with pH-dependent solubility. Int J Pharm 413 (2011), 237–244.
12. [12] Sarnes, A., Kovalainen, M., Hakkinen, M.R., et al. Nanocrystal-based per-oral itraconazole delivery: superior in vitro dissolution enhancement versus Sporanox(R) is not realized in in vivo drug absorption. J Control Release 180 (2014), 109–116.
13. [13] Sun, W., Ni, R., Zhang, X., et al. Spray drying of a poorly water-soluble drug nanosuspension for tablet preparation: formulation and process optimization with bioavailability evaluation. Drug Dev Ind Pharm 41 (2015), 927–933.
14. [14] Taupitz, T., Dressman, J.B., Buchanan, C.M., et al. Cyclodextrin-water soluble polymer ternary complexes enhance the solubility and dissolution behaviour of poorly soluble drugs.Case example: itraconazole. Eur J Pharm Biopharm 83 (2013), 378–387.
15. [15] Van Eerdenbrugh, B., Van Speybroeck, M., Mols, R., et al. Itraconazole/TPGS/Aerosil200 solid dispersions: characterization, physical stability and in vivo performance. Eur J Pharm Sci 38 (2009), 270–278.
16. [16] Yi, Y., Yoon, H.J., Kim, B.O., et al. A mixed polymeric micellar formulation of itraconazole: characteristics, toxicity and pharmacokinetics. J Control Release 117 (2007), 59–67.
17. [17] Mezghrani, O., Ke, X., Bourkaib, N., et al. Optimized self-microemulsifying drug delivery systems (SMEDDS) for enhanced oral bioavailability of astilbin. Pharmazie 66 (2011), 754–760.
18. [18] Tang, J., Wei, H., Liu, H., et al. Pharmacokinetics and biodistribution of itraconazole in rats and mice following intravenous administration in a novel liposome formulation. Drug Deliv 17 (2010), 223–230.
19. [19] Wu, W., Lu, Y., Qi, J., Oral delivery of liposomes. Ther Deliv 6 (2015), 1239–1241.
20. [20] Ates, M., Kaynak, M.S., Sahin, S., Effect of permeability enhancers on paracellular permeability of acyclovir. J Pharm Pharmacol 68:6 (2016), 781–790.
21. [21] Baldwin, A.M., Ilsley, A.H., Kluger, M.T., et al. Assessment of a new infusion pump for epidural PCA. Anaesth Intensive Care 19 (1991), 246–250.
22. [22] Conacher, M., Alexander, J., Brewer, J.M., Oral immunisation with peptide and protein antigens by formulation in lipid vesicles incorporating bile salts (bilosomes). Vaccine 19 (2001), 2965–2974.
23. [23] Guan, P., Lu, Y., Qi, J., et al. Enhanced oral bioavailability of cyclosporine A by liposomes containing a bile salt. Int J Nanomedicine 6 (2011), 965–974.
24. [24] Wang, J., Sun, J., Chen, Q., et al. Star-shape copolymer of lysine-linked di-tocopherol polyethylene glycol 2000 succinate for doxorubicin delivery with reversal of multidrug resistance. Biomaterials 33 (2012), 6877–6888.
25. [25] Han, X., Li, Z., Sun, J., et al. Stealth CD44-targeted hyaluronic acid supramolecular nanoassemblies for doxorubicin delivery: probing the effect of uncovalent pegylation degree on cellular uptake and blood long circulation. J Control Release 197 (2015), 29–40.
26. [26] Zhang, D., Pan, X., Wang, S., et al. Multifunctional Poly(methyl vinyl ether-co-maleic anhydride)-graft-hydroxypropyl-beta-cyclodextrin Amphiphilic Copolymer as an Oral High-Performance Delivery Carrier of Tacrolimus. Mol Pharm 12 (2015), 2337–2351.
27. [27] Liu, M., Cao, W., Sun, Y., et al. Preparation, characterization and in vivo evaluation of formulation of repaglinide with hydroxypropyl-beta-cyclodextrin. Int J Pharm 477 (2014), 159–166.
28. [28] Wang, M., Sun, J., Zhai, Y., et al. Enteric polymer based on pH-responsive aliphatic polycarbonate functionalized with vitamin E to facilitate oral delivery of tacrolimus. Biomacromolecules 16 (2015), 1179–1190.
29. [29] Guo, M., Fu, Q., Wu, C., et al. Rod shaped nanocrystals exhibit superior in vitro dissolution and in vivo bioavailability over spherical like nanocrystals: a case study of lovastatin. Colloids Surf B Biointerfaces 128 (2015), 410–418.
30. [30] Lian, H., Zhang, T., Sun, J., et al. Enhanced oral delivery of paclitaxel using acetylcysteine functionalized chitosan-vitamin E succinate nanomicelles based on a mucus bioadhesion and penetration mechanism. Mol Pharm 10 (2013), 3447–3458.
31. [31] Wu, C., Sun, L., Sun, J., et al. Profiling biopharmaceutical deciding properties of absorption of lansoprazole enteric-coated tablets using gastrointestinal simulation technology. Int J Pharm 453 (2013), 300–306.
32. [32] Fotaki, N., Klein, S., Mechanistic understanding of the effect of PPIs and acidic carbonated beverages on the oral absorption of itraconazole based on absorption modeling with appropriate in vitro data. Mol Pharm 10 (2013), 4016–4023.
33. [33] Kapsi, S.G., Ayres, J.W., Processing factors in development of solid solution formulation of itraconazole for enhancement of drug dissolution and bioavailability. Int J Pharm 229 (2001), 193–203.
34. [34] Yin, X., Daintree, L.S., Ding, S., et al. Itraconazole solid dispersion prepared by a supercritical fluid technique: preparation, in vitro characterization, and bioavailability in beagle dogs. Drug Des Devel Ther 9 (2015), 2801–2810.
35. [35] Luo, C., Sun, J., Sun, B., et al. Prodrug-based nanoparticulate drug delivery strategies for cancer therapy. Trends Pharmacol Sci 35 (2014), 556–566.
36. [36] Sun, J., Luo, C., Wang, Y., et al. The holistic 3M modality of drug delivery nanosystems for cancer therapy. Nanoscale 5 (2013), 845–859.